Biblio
“From Association to Intervention: The Alzheimer's Disease-Associated Processes and Targets (ADAPT) Ontology.”, J Alzheimers Dis, vol. 94, no. s1, pp. S87-S96, 2023.
, “JAD: A Forum for Philosophy in Science.”, J Alzheimers Dis, vol. 95, no. 2, pp. 411-413, 2023.
, “Exploring Reasons for Differential Vulnerability and Alzheimer's Disease Risk in Racial and Ethnic Minorities.”, J Alzheimers Dis, vol. 91, no. 1, pp. 495-506, 2023.
, “National Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive decline.”, Ann Intern Med, vol. 153, no. 3, pp. 176-81, 2010.
, “Propagation of tau pathology in a model of early Alzheimer's disease.”, Neuron, vol. 73, no. 4, pp. 685-97, 2012.
, “Malignant Brain Aging: The Formidable Link Between Dysregulated Signaling Through Mechanistic Target of Rapamycin Pathways and Alzheimer's Disease (Type 3 Diabetes).”, J Alzheimers Dis, vol. 95, no. 4, pp. 1301-1337, 2023.
, “Drivers: A Biologically Contextualized, Cross-Inferential View of the Epidemiology of Neurodegenerative Disorders.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1003-22, 2016.
, “The Behavioral and Psychological Symptoms of Dementia in Down Syndrome Scale (BPSD-DS II): Optimization and Further Validation.”, J Alzheimers Dis, vol. 81, no. 4, pp. 1505-1527, 2021.
, “Assessment of the Genetic Architecture of Alzheimer's Disease Risk in Rate of Memory Decline.”, J Alzheimers Dis, vol. 62, no. 2, pp. 745-756, 2018.
, “Sleep Deprivation, a Link Between Post-Traumatic Stress Disorder and Alzheimer's Disease.”, J Alzheimers Dis, vol. 79, no. 4, pp. 1443-1449, 2021.
, “Plasma Biomarkers of Alzheimer's Disease in African Americans.”, J Alzheimers Dis, vol. 79, no. 1, pp. 323-334, 2021.
, “Prospective Memory Impairments in Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia: Clinical and Neural Correlates.”, J Alzheimers Dis, vol. 50, no. 2, pp. 425-41, 2016.
, “MIND Diet, Common Brain Pathologies, and Cognition in Community-Dwelling Older Adults.”, J Alzheimers Dis, vol. 83, no. 2, pp. 683-692, 2021.
, “Hippocampal Lipid Homeostasis in APP/PS1 Mice is Modulated by a Complex Interplay Between Dietary DHA and Estrogens: Relevance for Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 2, pp. 459-81, 2016.
, “An Introduction to Ultrasensitive Assays for Plasma Tau Detection.”, J Alzheimers Dis, vol. 80, no. 4, pp. 1353-1362, 2021.
, “White Matter Hyperintensity Predicts the Risk of Incident Cognitive Decline in Community Dwelling Elderly.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1333-1341, 2018.
, “Cardiorespiratory Fitness and White Matter Neuronal Fiber Integrity in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 61, no. 2, pp. 729-739, 2018.
, “Low Plasma Cholinesterase Activities are Associated with Deficits in Spatial Orientation, Reduced Ability to Perform Basic Activities of Daily Living, and Low Body Mass Index in Patients with Progressed Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 3, pp. 801-13, 2016.
, “Anemia and Mild Cognitive Impairment in the German General Population.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1031-42, 2016.
, “Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).”, J Alzheimers Dis, vol. 49, no. 2, pp. 287-300, 2016.
, “Differential Impairment of Cognitive and Affective Mentalizing Abilities in Neurodegenerative Dementias: Evidence from Behavioral Variant of Frontotemporal Dementia, Alzheimer's Disease, and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1011-22, 2016.
, “Combined Socio-Behavioral Evaluation Improves the Differential Diagnosis Between the Behavioral Variant of Frontotemporal Dementia and Alzheimer's Disease: In Search of Neuropsychological Markers.”, J Alzheimers Dis, vol. 61, no. 2, pp. 761-772, 2018.
, “Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.”, J Alzheimers Dis, vol. 61, no. 1, pp. 169-183, 2018.
, “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
, “An Objective Method to Accurately Measure Cardiorespiratory Fitness in Older Adults Who Cannot Satisfy Widely Used Oxygen Consumption Criteria.”, J Alzheimers Dis, vol. 61, no. 2, pp. 601-611, 2018.
,